1NM-PP1 treatment of mice infected with Toxoplasma gondii

Tatsuki Sugi, Kentaro Kato, Kyousuke Kobayashi, Hitomi Kurokawa, Hitoshi Takemae, Haiyan Gong, Frances C. Recuenco, Tatsuya Iwanaga, Taisuke Horimoto, Hiroomi Akashi

研究成果: Article査読

14 被引用数 (Scopus)


Bumped kinase inhibitors (BKIs) target analog-sensitive kinases, which the genomes of mammals rarely encode. Previously, we demonstrated that a BKI effectively suppressed the in vitro replication of Toxoplasma gondii, the causative pathogen of toxoplasmosis, by targeting T. gondii calcium-dependent protein kinase 1 (TgCDPK1) (Eukaryotic Cell, 9: 667-670). Here, we examined whether the BKI 1NM-PP1 reduced parasite replication in vivo. A high dose of 1NM-PP1, by intraperitoneal injection, just before the parasite inoculation effectively reduced the parasite load in the brains, livers, and lungs of T. gondii-infected mice, however, a low dose of 1NMPP1 with oral administration didn't change the survival rates of infected mice.

ジャーナルJournal of Veterinary Medical Science
出版ステータスPublished - 2011 10

ASJC Scopus subject areas

  • veterinary(all)

フィンガープリント 「1NM-PP1 treatment of mice infected with Toxoplasma gondii」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。